Predicted protein targets (top 10)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | AURKA | O14965 | 4/20 | 0.47 |
| ▸ | CCNA2 | P20248 | 4/20 | 0.47 |
| ▸ | CDK2 | P24941 | 4/20 | 0.47 |
| ▸ | TTK | P33981 | 4/20 | 0.47 |
| ▸ | FYN | P06241 | 4/20 | 0.47 |
| ▸ | ROCK2 | O75116 | 9/20 | 0.46 |
| ▸ | AURKB | Q96GD4 | 1/20 | 0.45 |
| ▸ | AAK1 | Q2M2I8 | 1/20 | 0.45 |
| ▸ | ROCK1 | Q13464 | 2/20 | 0.43 |
| ▸ | NR2E3 | Q9Y5X4 | 1/20 | 0.42 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL5754846 | 0.92 | ROCK2 (0.47) | AURKACCNA2CDK2TTKFYN | |
| SCHEMBL5755889 | 0.84 | PDE10A (0.50) | AURKACCNA2CDK2TTKFYN | |
| SCHEMBL6480489 | 0.82 | ITK (0.46) | AURKACCNA2CDK2TTKFYN | |
| SCHEMBL2246941 | 0.82 | CASP3 (0.55) | NR2E3 | |
| SCHEMBL6478358 | 0.81 | NTRK1 (0.57) | — | |
| SCHEMBL6479954 | 0.78 | ROCK2 (0.51) | AURKAFYNROCK2ROCK1 | |
| SCHEMBL5756127 | 0.76 | TNIK (0.50) | AURKACCNA2CDK2TTKFYN | |
| SCHEMBL5754049 | 0.76 | MDM4 (0.41) | AURKACCNA2CDK2TTKFYN | |
| SCHEMBL6481076 | 0.75 | PDE10A (0.51) | AURKACCNA2CDK2TTKFYN | |
| SCHEMBL5815787 | 0.74 | KCNQ2 (0.49) | AURKACCNA2CDK2TTKFYN |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1648884-A2 | PYRAZOLYL-INDOLE DERIVATIVES ACTIVE AS KINASE INHIBITORS, PROCESS FOR THEIR PREPARATION AND PHARMACEUTICAL COMPOSITIONS COMPRISING THEM | Pharmacia Italia S.p.A. (IT) | 2006-04-26 | — | — | EP | disclosed |
| US-20050032869-A1 | Pyrazolyl-indole derivatives active as kinase inhibitors, process for their preparation and pharmaceutical compositions comprising them | PHARMACIA ITALIA S.P.A. (IT) | 2005-02-10 | — | — | US | disclosed |
| WO-2005005414-A2 | PYRAZOLYL-INDOLE DERIVATIVES ACTIVE AS KINASE INHIBITORS, PROCESS FOR THEIR PREPARATION AND PHARMACEUTICAL COMPOSITIONS COMPRISING THEM | PHARMACIA ITALIA S.P.A. (IT) | 2005-01-20 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20050032869-A1 | Pyrazolyl-indole derivatives active as kinase inhibitors, process for their preparation and pharmaceutical compositions comprising them | MAP3K9, MAP3K20, MAP3K19 | AURKA 136/4885CCNA2 1043/4885CDK2 95/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.